{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T20:32:54Z","timestamp":1744230774010},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Funct Integr Genomics"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>Immunotherapy has yielded encouraging results in the treatment of advanced hepatocellular carcinoma (HCC). However, the relationship between epithelial-mesenchymal transition (EMT) and immunotherapy for HCC has not been adequately explained. In this study, we comprehensively analyzed a bulk RNA sequence dataset of 365 HCC patients in The Cancer Genome Atlas (TCGA) dataset. Subsequently, we constructed a prognostic signature based on 6 EMT-related genes and divided 365 HCC patients into high- and low-risk groups. The predictive efficacy of the signature was well validated in different clinical subgroups and in two independent external datasets. We further explored the relationship between prognostic signature and immunotherapy response in terms of immune cell infiltration, somatic mutations, tumor mutation burden (TMB), microsatellite instability (MSI), immune checkpoint\u2013associated gene expression, single-nucleotide variants (SNV) neoantigens, cancer testicular antigens (CTA) scores, and tumor immune dysfunction and exclusion (TIDE) scores. We validated the predictive efficacy of prognostic signature for immunotherapy response using external independent immunotherapy data. Real-time quantitative polymerase chain reaction (qRT-PCR) was used to validate EMT-related gene overexpression in HCC tissue samples. Prognostic signature was an independent risk factor affecting the prognosis of HCC patients and has shown superiority in predicting patient survival compared to other clinical factors. Compared with the low-risk group, the proportion of Activated_CD4_T_cell, Type_2_T_helper_cel, and macrophages were higher in the tumor microenvironment of HCC patients in the high-risk group, while the Activated_CD8_T_cell and CD56bright_natural_killer_cell proportions were lower. The prognostic signature was positively correlated with TMB scores, MSI scores, SNV neoantigens scores, expression levels of immune checkpoint\u2013related genes, and TIDE scores, and patients in the high-risk group were more suitable for immunotherapy. qRT-PCR confirms overexpression of 6 EMT-related genes in HCC tissues for the construction of prognostic signature. Our novel prognostic signature can effectively predict the prognosis and immunotherapy response of HCC patients. In the future, it will be an effective tool for physicians to screen suitable immunotherapy populations and improve response rates and overall survival (OS).<\/jats:p>","DOI":"10.1007\/s10142-022-00933-w","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T02:02:30Z","timestamp":1671501750000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Construction and validation of a novel signature based on epithelial-mesenchymal transition\u2013related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment"],"prefix":"10.1007","volume":"23","author":[{"given":"Biao","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shichun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"issue":"12","key":"933_CR1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","volume":"3","author":"T Akinyemiju","year":"2017","unstructured":"Akinyemiju T, Abera S, Ahmed M et al (2017) The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 3(12):1683\u20131691. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3055","journal-title":"JAMA Oncol"},{"issue":"1","key":"933_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.canlet.2011.06.001","volume":"310","author":"J Cheng","year":"2011","unstructured":"Cheng J, Xie HY, Xu X et al (2011) NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. Cancer Lett 310(1):35\u201345. https:\/\/doi.org\/10.1016\/j.canlet.2011.06.001","journal-title":"Cancer Lett"},{"key":"933_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acr.2020.10.001","volume":"149","author":"S Chidambaranathan-Reghupaty","year":"2021","unstructured":"Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D (2021) Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res 149:1\u201361. https:\/\/doi.org\/10.1016\/bs.acr.2020.10.001","journal-title":"Adv Cancer Res"},{"issue":"8","key":"933_CR4","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico A, Silva TC, Olsen C et al (2016) TCGAbiolinks: an R\/bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res 44(8):e71. https:\/\/doi.org\/10.1093\/nar\/gkv1507","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"933_CR5","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"EASL-EORTC clinical practice guidelines","year":"2012","unstructured":"EASL-EORTC clinical practice guidelines (2012) management of hepatocellular carcinoma. J Hepatol 56(4):908\u2013943. https:\/\/doi.org\/10.1016\/j.jhep.2011.12.001","journal-title":"J Hepatol"},{"issue":"12","key":"933_CR6","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1080\/14737140.2018.1535315","volume":"18","author":"F Finkelmeier","year":"2018","unstructured":"Finkelmeier F, Waidmann O, Trojan J (2018) Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther 18(12):1169\u20131175. https:\/\/doi.org\/10.1080\/14737140.2018.1535315","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"933_CR7","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L et al (2017) Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 16(11):2598\u20132608. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0386","journal-title":"Mol Cancer Ther"},{"key":"933_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40425-016-0153-x","volume":"4","author":"C Grigg","year":"2016","unstructured":"Grigg C, Rizvi NA (2016) PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? J Immunother Cancer 4:48. https:\/\/doi.org\/10.1186\/s40425-016-0153-x","journal-title":"J Immunother Cancer"},{"key":"933_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma 14:7. https:\/\/doi.org\/10.1186\/1471-2105-14-7","journal-title":"BMC Bioinforma"},{"issue":"22","key":"933_CR10","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu TE, Pluzanski A et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378(22):2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1801946","journal-title":"N Engl J Med"},{"issue":"5","key":"933_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4132\/jptm.2021.07.26","volume":"55","author":"YJ Hwang","year":"2021","unstructured":"Hwang YJ, Lee Y, Park H et al (2021) Prognostic significance of viable tumor size measurement in hepatocellular carcinomas after preoperative locoregional treatment. J Pathol Transl Med 55(5):338\u2013348. https:\/\/doi.org\/10.4132\/jptm.2021.07.26","journal-title":"J Pathol Transl Med"},{"issue":"8","key":"933_CR12","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/13543784.2019.1649657","volume":"28","author":"GA Ingles","year":"2019","unstructured":"Ingles GA, Au L, Mason R et al (2019) Building on the anti-PD1\/PD-L1 backbone: combination immunotherapy for cancer. Expert Opin Investig Drugs 28(8):695\u2013708. https:\/\/doi.org\/10.1080\/13543784.2019.1649657","journal-title":"Expert Opin Investig Drugs"},{"issue":"24","key":"933_CR13","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.3748\/wjg.v25.i24.2977","volume":"25","author":"MP Johnston","year":"2019","unstructured":"Johnston MP, Khakoo SI (2019) Immunotherapy for hepatocellular carcinoma: current and future. World J Gastroenterol 25(24):2977\u20132989. https:\/\/doi.org\/10.3748\/wjg.v25.i24.2977","journal-title":"World J Gastroenterol"},{"key":"933_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bbrc.2021.05.051","volume":"563","author":"H Kim","year":"2021","unstructured":"Kim H, Lee JY, Park SJ et al (2021) ZNF746\/PARIS promotes the occurrence of hepatocellular carcinoma. Biochem Biophys Res Commun 563:98\u2013104. https:\/\/doi.org\/10.1016\/j.bbrc.2021.05.051","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"933_CR15","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/hep.29904","volume":"68","author":"Y Kurebayashi","year":"2018","unstructured":"Kurebayashi Y, Ojima H, Tsujikawa H et al (2018) Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatol 68(3):1025\u20131041. https:\/\/doi.org\/10.1002\/hep.29904","journal-title":"Hepatol"},{"key":"933_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13046-015-0245-3","volume":"34","author":"X Lv","year":"2015","unstructured":"Lv X, Li L, Lv L et al (2015) HOXD9 promotes epithelial-mesenchymal transition and cancer metastasis by ZEB1 regulation in hepatocellular carcinoma. J Exp Clin Cancer Res 34:133. https:\/\/doi.org\/10.1186\/s13046-015-0245-3","journal-title":"J Exp Clin Cancer Res"},{"key":"933_CR17","doi-asserted-by":"publisher","first-page":"635243","DOI":"10.3389\/fmolb.2021.635243","volume":"8","author":"X Li","year":"2021","unstructured":"Li X, Wang Y, Ye X et al (2021) Locoregional combined with systemic therapies for advanced hepatocellular carcinoma: an inevitable trend of rapid development. Front Mol Biosci 8:635243. https:\/\/doi.org\/10.3389\/fmolb.2021.635243","journal-title":"Front Mol Biosci"},{"issue":"1","key":"933_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ccell.2021.11.012","volume":"40","author":"F Newell","year":"2022","unstructured":"Newell F, Pires DSI, Johansson PA et al (2022) Multiomic profiling of checkpoint inhibitor-treated melanoma: identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell 40(1):88\u2013102. https:\/\/doi.org\/10.1016\/j.ccell.2021.11.012","journal-title":"Cancer Cell"},{"issue":"4","key":"933_CR19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14(4):847\u2013856. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0983","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"933_CR20","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1038\/s41388-020-1249-9","volume":"39","author":"DJ Pinato","year":"2020","unstructured":"Pinato DJ, Guerra N, Fessas P et al (2020) Immune-based therapies for hepatocellular carcinoma. Oncogene 39(18):3620\u20133637. https:\/\/doi.org\/10.1038\/s41388-020-1249-9","journal-title":"Oncogene"},{"issue":"1","key":"933_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1001\/jamaoncol.2020.3381","volume":"7","author":"M Pinter","year":"2021","unstructured":"Pinter M, Jain RK, Duda DG (2021) The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review[J]. JAMA Oncol 7(1):113\u2013123. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3381","journal-title":"JAMA Oncol"},{"key":"933_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.mehy.2018.05.005","volume":"116","author":"BD Qin","year":"2018","unstructured":"Qin BD, Jiao XD, Zang YS (2018) Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1\/PD-L1 immunotherapy. Med Hypotheses 116:111\u2013113. https:\/\/doi.org\/10.1016\/j.mehy.2018.05.005","journal-title":"Med Hypotheses"},{"issue":"19","key":"933_CR23","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1073\/pnas.1802279115","volume":"115","author":"XY Qin","year":"2018","unstructured":"Qin XY, Suzuki H, Honda M et al (2018) Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid. Proc Natl Acad Sci U S A 115(19):4969\u20134974. https:\/\/doi.org\/10.1073\/pnas.1802279115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"933_CR24","doi-asserted-by":"publisher","unstructured":"Rizzo A, Ricci A D, Brandi G (2021) PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers (Basel), 13(3). https:\/\/doi.org\/10.3390\/cancers13030558.","DOI":"10.3390\/cancers13030558"},{"issue":"1","key":"933_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinforma 26(1):139\u2013140. https:\/\/doi.org\/10.1093\/bioinformatics\/btp616","journal-title":"Bioinforma"},{"key":"933_CR26","doi-asserted-by":"publisher","first-page":"757804","DOI":"10.3389\/fimmu.2021.757804","volume":"12","author":"V Roudko","year":"2021","unstructured":"Roudko V, Cimen BC, Greenbaum B et al (2021) Lynch syndrome and MSI-H cancers: from mechanisms to \u201coff-the-shelf\u201d cancer vaccines. Front Immunol 12:757804. https:\/\/doi.org\/10.3389\/fimmu.2021.757804","journal-title":"Front Immunol"},{"issue":"4","key":"933_CR27","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s12072-022-10354-3","volume":"16","author":"Y Shi","year":"2022","unstructured":"Shi Y, Wang J, Huang G et al (2022) A novel epithelial-mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma. Hepatol Int 16(4):906\u2013917. https:\/\/doi.org\/10.1007\/s12072-022-10354-3","journal-title":"Hepatol Int"},{"issue":"3","key":"933_CR28","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/hep.26188","volume":"57","author":"HX Sun","year":"2013","unstructured":"Sun HX, Xu Y, Yang XR et al (2013) Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3\/ E2F transcription factor 1-dependent apoptotic pathway. Hepatol 57(3):1088\u20131097. https:\/\/doi.org\/10.1002\/hep.26188","journal-title":"Hepatol"},{"key":"933_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fonc.2020.00183","volume":"10","author":"C Tao","year":"2020","unstructured":"Tao C, Huang K, Shi J et al (2020) Genomics and prognosis analysis of epithelial-mesenchymal transition in glioma. Front Oncol 10:183. https:\/\/doi.org\/10.3389\/fonc.2020.00183","journal-title":"Front Oncol"},{"key":"933_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.canlet.2017.11.014","volume":"414","author":"F Teng","year":"2018","unstructured":"Teng F, Meng X, Kong L et al (2018) Progress and challenges of predictive biomarkers of anti PD-1\/PD-L1 immunotherapy: a systematic review. Cancer Lett 414:166\u2013173. https:\/\/doi.org\/10.1016\/j.canlet.2017.11.014","journal-title":"Cancer Lett"},{"key":"933_CR31","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.12659\/msm.905262","volume":"23","author":"ZY Wang","year":"2017","unstructured":"Wang ZY, Yang J, Liu CK et al (2017) High expression of retinoblastoma-binding protein 2 (RBP2) in patients with hepatocellular carcinoma and its prognostic significance. Med Sci Monit 23:2736\u20132744. https:\/\/doi.org\/10.12659\/msm.905262","journal-title":"Med Sci Monit"},{"key":"933_CR32","doi-asserted-by":"publisher","first-page":"711433","DOI":"10.3389\/fimmu.2021.711433","volume":"12","author":"Q Xu","year":"2021","unstructured":"Xu Q, Chen S, Hu Y et al (2021) Landscape of immune microenvironment under immune cell infiltration pattern in breast cancer. Front Immunol 12:711433. https:\/\/doi.org\/10.3389\/fimmu.2021.711433","journal-title":"Front Immunol"},{"issue":"1","key":"933_CR33","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1186\/s12935-021-02326-8","volume":"21","author":"D Xu","year":"2021","unstructured":"Xu D, Wang Y, Wu J et al (2021) Identification and clinical validation of EMT-associated prognostic features based on hepatocellular carcinoma. Cancer Cell Int 21(1):621. https:\/\/doi.org\/10.1186\/s12935-021-02326-8","journal-title":"Cancer Cell Int"},{"issue":"25","key":"933_CR34","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 377(25):2500\u20132501. https:\/\/doi.org\/10.1056\/NEJMc1713444","journal-title":"N Engl J Med"},{"issue":"1","key":"933_CR35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","volume":"17","author":"M Yi","year":"2018","unstructured":"Yi M, Jiao D, Xu H et al (2018) Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors. Mol Cancer 17(1):129. https:\/\/doi.org\/10.1186\/s12943-018-0864-3","journal-title":"Mol Cancer"},{"issue":"5","key":"933_CR36","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y et al (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16(5):284\u2013287. https:\/\/doi.org\/10.1089\/omi.2011.0118","journal-title":"OMICS"},{"issue":"12","key":"933_CR37","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.tibs.2018.09.004","volume":"43","author":"J Zhang","year":"2018","unstructured":"Zhang J, Dang F, Ren J et al (2018) Biochemical aspects of PD-L1 regulation in cancer immunotherapy. Trends Biochem Sci 43(12):1014\u20131032. https:\/\/doi.org\/10.1016\/j.tibs.2018.09.004","journal-title":"Trends Biochem Sci"},{"issue":"3","key":"933_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000488035","volume":"7","author":"J Zhou","year":"2018","unstructured":"Zhou J, Sun HC, Wang Z et al (2018) Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer 7(3):235\u2013260. https:\/\/doi.org\/10.1159\/000488035","journal-title":"Liver Cancer"}],"container-title":["Functional &amp; Integrative Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-022-00933-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10142-022-00933-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-022-00933-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T08:11:41Z","timestamp":1679299901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10142-022-00933-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["933"],"URL":"https:\/\/doi.org\/10.1007\/s10142-022-00933-w","relation":{},"ISSN":["1438-793X","1438-7948"],"issn-type":[{"value":"1438-793X","type":"print"},{"value":"1438-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"assertion":[{"value":"24 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"6"}}